💉 Retatrutide vs Tirzepatide vs Semaglutide

Which Peptide Is Right for Your Research? Full Breakdown Below


GLP-1 based peptides are currently leading the way in weight loss and metabolic research. Among the most discussed are Retatrutide, Tirzepatide (Tirz), and Semaglutide (Sema) — but how do they actually differ?


Let’s take a closer look at their mechanisms, reported effects, and ideal research applications.




🔬 Mechanism of Action​


  • Retatrutide – Triple agonist: GLP-1 + GIP + Glucagon
    ➤ The newest and most aggressive model peptide in this class.
  • Tirzepatide – Dual agonist: GLP-1 + GIP
    ➤ Balanced approach for fat loss and insulin-related studies.
  • Semaglutide – Single agonist: GLP-1 only
    ➤ Reliable, stable, and ideal for long-term or comparative research.



⚖️ Reported Research Outcomes​


  • Retatrutide:
    ✅ Most aggressive appetite suppression
    ✅ Up to 24% body weight reduction in clinical models
    ✅ Suitable for advanced, short-cycle high-intensity studies
  • Tirzepatide:
    ✅ Consistent fat reduction (15–20%)
    ✅ Weekly protocols, excellent metabolic profile
    ✅ Good for intermediate research setups
  • Semaglutide:
    ✅ 10–15% weight loss effect
    ✅ Fewer GI-related issues
    ✅ Ideal for beginners and low-intensity studies



🧪 Summary Table​


Retatrutide⭐⭐⭐⭐⭐ | For advanced fat-loss/metabolic models
Tirzepatide⭐⭐⭐⭐ | For GLP+GIP dual-pathway studies
Semaglutide⭐⭐⭐ | For stable, long-term baseline research




💡 Suggested Research Formats (Most Common)​


  • Retatrutide: 10mg/vial
  • Tirzepatide: 10mg/vial
  • Semaglutide: 10mg/vial

📎 COAs and lab verification available on request.




⚠️ Important Disclaimer​


All compounds listed here are strictly intended for research use only.
They are not for human consumption or therapeutic/medical use of any kind.




💬 Let’s Discuss​


Have you tried any of these in your research?
Drop your feedback or questions below 👇
We’re happy to help clarify mechanisms, supply details, or testing procedures.
 
What about Tesa ?

🔬 Research Highlights of Tesamorelin​


🔹 Reduction of Visceral Fat (VAT)
Tesamorelin is one of the few peptides shown to significantly reduce abdominal visceral fat in research settings. It has been especially studied in metabolic syndrome and HIV-related fat redistribution models.


🔹 Increase in IGF-1 Levels
Studies show that Tesamorelin consistently elevates GH-axis markers, particularly IGF-1, which may support anabolic pathways and metabolic regulation.


🔹 Minimal Impact on Blood Sugar
Compared to some GH-related compounds, Tesamorelin has a lower tendency to disrupt glucose levels, making it suitable for studies focusing on metabolic stability.


🔹 Skin Elasticity and Cognitive Studies
Preliminary research has explored its potential in improving skin structure and cognitive function, though further validation is still needed.
 
Back
Top